lenacapavir's trial was taking patients with Plasm

lenacapavir's trial was taking patients with Plasma HIV-1 RNA ≥ 5,000 copies/mL but ≤ 400,000 copies/mL. Those patients were treatment naive or no treatment for 12 weeks. I would expect the higher range copies/ml.

At average of 100,000 copies/ml that 66% reduction would be 33,000 copies/ ml vs. 50 copies/ml for leronlimab. >= 200 copies/ml is considered excellent treatment.